Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2015

Published: Oct, 2015 | Pages: 285 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2015', provides an overview of the Non-Alcoholic Steatohepatitis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Non-Alcoholic Steatohepatitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Non-Alcoholic Steatohepatitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Non-Alcoholic Steatohepatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Non-Alcoholic Steatohepatitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Non-Alcoholic Steatohepatitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Non-Alcoholic Steatohepatitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents
2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Non-Alcoholic Steatohepatitis Overview 10
Therapeutics Development 11
Pipeline Products for Non-Alcoholic Steatohepatitis - Overview 11
Pipeline Products for Non-Alcoholic Steatohepatitis - Comparative Analysis 12
Non-Alcoholic Steatohepatitis - Therapeutics under Development by Companies 13
Non-Alcoholic Steatohepatitis - Therapeutics under Investigation by Universities/Institutes 16
Non-Alcoholic Steatohepatitis - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Non-Alcoholic Steatohepatitis - Products under Development by Companies 20
Non-Alcoholic Steatohepatitis - Products under Investigation by Universities/Institutes 25
Non-Alcoholic Steatohepatitis - Companies Involved in Therapeutics Development 26
AlbireoPharma 26
Aquinox Pharmaceuticals Inc. 27
Ardelyx, Inc. 28
Arisaph Pharmaceuticals, Inc. 29
BiOrion Technologies B.V. 30
Boehringer Ingelheim GmbH 31
Bristol-Myers Squibb Company 32
Cardax Pharmaceuticals, Inc. 33
Cerenis Therapeutics Holding SA 34
Conatus Pharmaceuticals Inc. 35
Connexios Life Sciences Pvt. Ltd. 36
Daiichi Sankyo Company, Limited 37
Dr. Falk Pharma GmbH 38
DURECT Corporation 39
Dynavax Technologies Corporation 40
Enanta Pharmaceuticals, Inc. 41
Exicure, Inc. 42
Galectin Therapeutics, Inc. 43
Galmed International Ltd. 44
Genfit SA 45
GenKyoTex S.A. 46
Gilead Sciences, Inc. 47
iCo Therapeutics Inc. 48
Immuron Limited 49
Intercept Pharmaceuticals, Inc. 50
Isis Pharmaceuticals, Inc. 51
Jenrin Discovery, Inc. 52
Kissei Pharmaceutical Co., Ltd. 53
Kyorin Pharmaceutical Co., Ltd. 54
Merck & Co., Inc. 55
Mochida Pharmaceutical Co., Ltd. 56
NGM Biopharmaceuticals, Inc. 57
Nimbus Therapeutics, LLC 58
Nippon Chemiphar Co., Ltd. 59
Novartis AG 60
Novo Nordisk A/S 61
ProMetic Life Sciences Inc. 62
Protalix BioTherapeutics, Inc. 63
Regulus Therapeutics Inc. 64
RuiYi Inc. 65
Shire Plc 66
Stelic Institute & Co. 67
Therapix Biosciences Ltd 68
Tobira Therapeutics, Inc. 69
Vascular Biogenics Ltd. 70
Verva Pharmaceuticals Limited 71
Viking Therapeutics, Inc. 72
Virobay Inc. 73
Zafgen Inc. 74
Zydus Cadila Healthcare Limited 75
Non-Alcoholic Steatohepatitis - Therapeutics Assessment 76
Assessment by Monotherapy Products 76
Assessment by Combination Products 77
Assessment by Target 78
Assessment by Mechanism of Action 82
Assessment by Route of Administration 85
Assessment by Molecule Type 87
Drug Profiles 89
(leucine + metformin + sildenafil) - Drug Profile 89
A-4250 - Drug Profile 90
AM-0010 - Drug Profile 91
AQX-1125 - Drug Profile 92
Aramchol - Drug Profile 94
ARI-3037MO - Drug Profile 96
bertilimumab - Drug Profile 97
BMS-986036 - Drug Profile 99
BOT-191 - Drug Profile 101
CDX-085 - Drug Profile 102
cenicriviroc mesylate - Drug Profile 104
CER-209 - Drug Profile 106
CNX-014 - Drug Profile 107
CNX-023 - Drug Profile 108
CNX-024 - Drug Profile 109
CNX-025 - Drug Profile 110
DUR-928 - Drug Profile 111
DV-1179 - Drug Profile 112
elafibranor - Drug Profile 114
emricasan - Drug Profile 117
etanercept biosimilar - Drug Profile 119
GKT-831 - Drug Profile 120
GR-MD-02 - Drug Profile 121
icosapent ethyl - Drug Profile 124
IMM-124E - Drug Profile 125
ISIS-DGAT2Rx - Drug Profile 127
JD-5037 - Drug Profile 128
JKB-119 - Drug Profile 129
JKB-121 - Drug Profile 130
liraglutide (recombinant) - Drug Profile 131
LJN-452 - Drug Profile 134
MAT-8800 - Drug Profile 135
methazolamide - Drug Profile 136
MGL-3196 - Drug Profile 138
Monoclonal Antibody to Inhibit CD3 for Autoimmune Disorders, CNS Disorders, Infectious Diseases, Liver Diseases, Metabolic Disorders and Cardiovascular Diseases - Drug Profile 140
NC-101 - Drug Profile 142
NC-2400 - Drug Profile 143
ND-630 - Drug Profile 144
ND-654 - Drug Profile 145
NDI-010976 - Drug Profile 146
NGM-282 - Drug Profile 147
norursodeoxycholic acid - Drug Profile 148
NP-201 - Drug Profile 149
obeticholic acid - Drug Profile 150
Oligonucleotides for Non-Alcoholic Steatohepatitis - Drug Profile 153
PBI-4050 - Drug Profile 154
pentamidine isethionate - Drug Profile 155
Px-102 - Drug Profile 157
Px-103 - Drug Profile 159
PXS-4728A - Drug Profile 160
PZ-235 - Drug Profile 161
RDX-009 - Drug Profile 162
remogliflozin etabonate - Drug Profile 163
RG-125 - Drug Profile 166
RYI-018 - Drug Profile 167
saroglitazar - Drug Profile 168
SDP-051 - Drug Profile 169
selonsertib - Drug Profile 171
simtuzumab - Drug Profile 172
Small Molecule for Non-Alcoholic Steatohepatitis - Drug Profile 174
Small Molecule to Inhibit SCD-1 for Nonalcoholic Steatohepatitis - Drug Profile 175
Small Molecules to Activate AMPK for Fatty Liver Disease - Drug Profile 176
Small Molecules to Agonize Farnesoid X Receptor for Non-alcoholic Steatohepatitis and Primary Biliary Cirrhosis - Drug Profile 177
solithromycin - Drug Profile 178
SR-9238 - Drug Profile 180
STNM-09 - Drug Profile 181
TGFTX-3 Program - Drug Profile 182
tipelukast - Drug Profile 183
TRX-318 - Drug Profile 185
VB-201 - Drug Profile 186
VBY-376 - Drug Profile 188
VK-0214 - Drug Profile 189
VK-2809 - Drug Profile 190
volixibat potassium - Drug Profile 192
VVP-100-X - Drug Profile 193
ZGN-839 - Drug Profile 194
Non-Alcoholic Steatohepatitis - Recent Pipeline Updates 195
Non-Alcoholic Steatohepatitis - Dormant Projects 268
Non-Alcoholic Steatohepatitis - Discontinued Products 270
Non-Alcoholic Steatohepatitis - Product Development Milestones 271
Featured News & Press Releases 271
Appendix 278
Methodology 278
Coverage 278
Secondary Research 278
Primary Research 278
Expert Panel Validation 278
Contact Us 278
Disclaimer 279

List of Tables

Number of Products under Development for Non-Alcoholic Steatohepatitis, H2 2015 17
Number of Products under Development for Non-Alcoholic Steatohepatitis - Comparative Analysis, H2 2015 18
Number of Products under Development by Companies, H2 2015 20
Number of Products under Investigation by Universities/Institutes, H2 2015 22
Comparative Analysis by Late Stage Development, H2 2015 23
Comparative Analysis by Clinical Stage Development, H2 2015 24
Comparative Analysis by Early Stage Development, H2 2015 25
Products under Development by Companies, H2 2015 26
Products under Development by Companies, H2 2015 (Contd..1) 27
Products under Development by Companies, H2 2015 (Contd..2) 28
Products under Development by Companies, H2 2015 (Contd..3) 29
Products under Development by Companies, H2 2015 (Contd..4) 30
Products under Investigation by Universities/Institutes, H2 2015 31
Non-Alcoholic Steatohepatitis - Pipeline by AlbireoPharma, H2 2015 32
Non-Alcoholic Steatohepatitis - Pipeline by Aquinox Pharmaceuticals Inc., H2 2015 33
Non-Alcoholic Steatohepatitis - Pipeline by Ardelyx, Inc., H2 2015 34
Non-Alcoholic Steatohepatitis - Pipeline by Arisaph Pharmaceuticals, Inc., H2 2015 35
Non-Alcoholic Steatohepatitis - Pipeline by BiOrion Technologies B.V., H2 2015 36
Non-Alcoholic Steatohepatitis - Pipeline by Boehringer Ingelheim GmbH, H2 2015 37
Non-Alcoholic Steatohepatitis - Pipeline by Bristol-Myers Squibb Company, H2 2015 38
Non-Alcoholic Steatohepatitis - Pipeline by Cardax Pharmaceuticals, Inc., H2 2015 39
Non-Alcoholic Steatohepatitis - Pipeline by Cerenis Therapeutics Holding SA, H2 2015 40
Non-Alcoholic Steatohepatitis - Pipeline by Conatus Pharmaceuticals Inc., H2 2015 41
Non-Alcoholic Steatohepatitis - Pipeline by Connexios Life Sciences Pvt. Ltd., H2 2015 42
Non-Alcoholic Steatohepatitis - Pipeline by Daiichi Sankyo Company, Limited, H2 2015 43
Non-Alcoholic Steatohepatitis - Pipeline by Dr. Falk Pharma GmbH, H2 2015 44
Non-Alcoholic Steatohepatitis - Pipeline by DURECT Corporation, H2 2015 45
Non-Alcoholic Steatohepatitis - Pipeline by Dynavax Technologies Corporation, H2 2015 46
Non-Alcoholic Steatohepatitis - Pipeline by Enanta Pharmaceuticals, Inc., H2 2015 47
Non-Alcoholic Steatohepatitis - Pipeline by Exicure, Inc., H2 2015 48
Non-Alcoholic Steatohepatitis - Pipeline by Galectin Therapeutics, Inc., H2 2015 49
Non-Alcoholic Steatohepatitis - Pipeline by Galmed International Ltd., H2 2015 50
Non-Alcoholic Steatohepatitis - Pipeline by Genfit SA, H2 2015 51
Non-Alcoholic Steatohepatitis - Pipeline by GenKyoTex S.A., H2 2015 52
Non-Alcoholic Steatohepatitis - Pipeline by Gilead Sciences, Inc., H2 2015 53
Non-Alcoholic Steatohepatitis - Pipeline by iCo Therapeutics Inc., H2 2015 54
Non-Alcoholic Steatohepatitis - Pipeline by Immuron Limited, H2 2015 55
Non-Alcoholic Steatohepatitis - Pipeline by Intercept Pharmaceuticals, Inc., H2 2015 56
Non-Alcoholic Steatohepatitis - Pipeline by Isis Pharmaceuticals, Inc., H2 2015 57
Non-Alcoholic Steatohepatitis - Pipeline by Jenrin Discovery, Inc., H2 2015 58
Non-Alcoholic Steatohepatitis - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2015 59
Non-Alcoholic Steatohepatitis - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2015 60
Non-Alcoholic Steatohepatitis - Pipeline by Merck & Co., Inc., H2 2015 61
Non-Alcoholic Steatohepatitis - Pipeline by Mochida Pharmaceutical Co., Ltd., H2 2015 62
Non-Alcoholic Steatohepatitis - Pipeline by NGM Biopharmaceuticals, Inc., H2 2015 63
Non-Alcoholic Steatohepatitis - Pipeline by Nimbus Therapeutics, LLC, H2 2015 64
Non-Alcoholic Steatohepatitis - Pipeline by Nippon Chemiphar Co., Ltd., H2 2015 65
Non-Alcoholic Steatohepatitis - Pipeline by Novartis AG, H2 2015 66
Non-Alcoholic Steatohepatitis - Pipeline by Novo Nordisk A/S, H2 2015 67
Non-Alcoholic Steatohepatitis - Pipeline by ProMetic Life Sciences Inc., H2 2015 68
Non-Alcoholic Steatohepatitis - Pipeline by Protalix BioTherapeutics, Inc., H2 2015 69
Non-Alcoholic Steatohepatitis - Pipeline by Regulus Therapeutics Inc., H2 2015 70
Non-Alcoholic Steatohepatitis - Pipeline by RuiYi Inc., H2 2015 71
Non-Alcoholic Steatohepatitis - Pipeline by Shire Plc, H2 2015 72
Non-Alcoholic Steatohepatitis - Pipeline by Stelic Institute & Co., H2 2015 73
Non-Alcoholic Steatohepatitis - Pipeline by Therapix Biosciences Ltd, H2 2015 74
Non-Alcoholic Steatohepatitis - Pipeline by Tobira Therapeutics, Inc., H2 2015 75
Non-Alcoholic Steatohepatitis - Pipeline by Vascular Biogenics Ltd., H2 2015 76
Non-Alcoholic Steatohepatitis - Pipeline by Verva Pharmaceuticals Limited, H2 2015 77
Non-Alcoholic Steatohepatitis - Pipeline by Viking Therapeutics, Inc., H2 2015 78
Non-Alcoholic Steatohepatitis - Pipeline by Virobay Inc., H2 2015 79
Non-Alcoholic Steatohepatitis - Pipeline by Zafgen Inc., H2 2015 80
Non-Alcoholic Steatohepatitis - Pipeline by Zydus Cadila Healthcare Limited, H2 2015 81
Assessment by Monotherapy Products, H2 2015 82
Assessment by Combination Products, H2 2015 83
Number of Products by Stage and Target, H2 2015 85
Number of Products by Stage and Mechanism of Action, H2 2015 89
Number of Products by Stage and Route of Administration, H2 2015 92
Number of Products by Stage and Molecule Type, H2 2015 94
Non-Alcoholic Steatohepatitis Therapeutics - Recent Pipeline Updates, H2 2015 201
Non-Alcoholic Steatohepatitis - Dormant Projects, H2 2015 274
Non-Alcoholic Steatohepatitis - Dormant Projects (Contd..1), H2 2015 275
Non-Alcoholic Steatohepatitis - Discontinued Products, H2 2015 276